BiotechTube
Nitto Denko Avecia

Nitto Denko Avecia

Milford, United States· Est.
avecia.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Nitto Denko Avecia is a specialized oligonucleotide CDMO and a subsidiary of the Japanese materials science conglomerate Nitto Denko Corporation. With over 25 years of experience, the company offers end-to-end solutions for therapeutic oligonucleotide programs, including process development, analytical services, and drug substance manufacturing under cGMP. Recent milestones include a successful FDA inspection and an evaluation agreement with Codexis to explore novel synthesis platforms, positioning it as a key player in the growing oligo therapeutics market.

AntibodiesBiologicsSmall Molecules

Technology Platform

OliGrow® service platform for integrated oligonucleotide process development, analytical development, and manufacturing.

Opportunities

The rapidly expanding oligonucleotide therapeutics market drives strong demand for specialized CDMO services.
Recent regulatory successes (FDA, ANVISA) enhance global credibility and attract new clients.
Exploring next-generation synthesis platforms, like Codexis's ECO Synthesis®, could provide a competitive technological advantage for siRNA manufacturing.

Risk Factors

Revenue is dependent on the success and timing of client programs, creating concentration and pipeline risk.
The competitive landscape for oligonucleotide CDMO services is intensifying, potentially leading to margin pressure.
Operational risks include maintaining strict GMP compliance across facilities and managing complex supply chains for specialized raw materials.

Competitive Landscape

Avecia competes with other specialized oligonucleotide CDMOs (e.g., ST Pharm, CordenPharma, Danaher/Integrated DNA Technologies) and large, diversified CDMOs (e.g., Lonza, Catalent) that have oligo capabilities. Its differentiation is based on over 25 years of focused experience, a fully integrated service platform (OliGrow®), and a strong regulatory track record. The backing by Nitto Denko provides financial stability and materials science expertise.

More companies in Biologics / Biosimilars →More companies in United States →